title: Ursodeoxycholic acid decreases sodium-glucose cotransporter (SGLT2) expression and oxidative stress in the kidney of diabetic rats.
abstract: Oxidative stress has been associated with diabetic complications like nephropathies. Recent studies indicate that ursodeoxycholic acid (UDCA) may be beneficial preventing diabetes-induced oxidative stress and secondary complications. Thus, we study if the UDCA-treatment decreases the expression of sodium-glucose cotransporter (SGLT2) and the oxidative stress in the kidney of diabetic rats.
  
  
  METHODS
  The diabetes model was established by intraperitoneal injection of streptozotocin (50mg/kg). SGLT2 expression was evaluated by western blot and RT-PCR. Oxidative stress was assessed by catalase (CAT), glutathione peroxidase (GPx) and superoxide dismutase activities (SOD) and immunohistochemical analysis of 3-nitrotyrosine (3-NT).
  
  
  RESULTS
  Streptozotocin-induced diabetes caused hyperglycemia and lower body weight. The SGLT2 expression and mRNA levels increased in cortex of kidney from diabetic rats. The CAT activity decreased in cortex and medulla from diabetic rats, otherwise the GPx activity increased. Furthermore the 3-NT staining of kidney from diabetic rats increased compared to control rats. The UDCA treatment was able to decrease hyperglycemia and prevents the SGLT2 over-expression, restores the CAT and GPX activities and decreases 3-NT staining.
  
  
  CONCLUSIONS
  The UDCA treatment prevents the over-expression of SGLT2 and oxidative stress in kidney of diabetic rats.
authors.affiliation: Department of Nephrology, Instituto Nacional de Cardiología Ignacio Chavez México City, 14080, Mexico. horace_33@yahoo.com.mx
authors.forename: Horacio
authors.initials: H
authors.lastname: Osorio
authors.forename: Israel
authors.initials: I
authors.lastname: Coronel
authors.forename: Abraham
authors.initials: A
authors.lastname: Arellano
authors.forename: Martha
authors.initials: M
authors.lastname: Franco
authors.forename: Bruno
authors.initials: B
authors.lastname: Escalante
authors.forename: Rocío
authors.initials: R
authors.lastname: Bautista
mesh_terms: D000818:Animals; D001786:Blood Glucose / Q000378:metabolism; D002374:Catalase / Q000378:metabolism; D003921:Diabetes Mellitus, Experimental / Q000188:drug therapy* / Q000378:metabolism; D003928:Diabetic Nephropathies / Q000188:drug therapy* / Q000378:metabolism; D007150:Immunohistochemistry; D007668:Kidney / Q000378:metabolism*; D008297:Male; D018384:Oxidative Stress / Q000187:drug effects*; D051381:Rats; D017208:Rats, Wistar; D051297:Sodium-Glucose Transporter 2 / Q000378:metabolism*; D014580:Ursodeoxycholic Acid / Q000494:pharmacology*
chemical_list: D001786:Blood Glucose; C490300:Slc5a2 protein, rat; D051297:Sodium-Glucose Transporter 2; D014580:Ursodeoxycholic Acid; D002374:Catalase